CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter...
Coverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung
NavDx ® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers Expands CareDx’s estimated addressable market...
Sharpens focus on U.S. precision medicine Testing Services and Patient & Digital Solutions
Growing body of evidence supports AlloSure ® as a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes Data across...
AlloSure ® Kidney elevations are associated with increased risk of graft dysfunction and loss in kidney transplant recipients Data...
CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant...
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare...
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare...
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...